In the clinic: Ongoing clinical trials evaluating c-MET-inhibiting drugs

Neelesh Sharma, Alex Adjei

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

The c-MET (mesenchymal–epithelial transition factor) pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination. The c-MET receptor tyrosine kinase can be activated via gene mutation, gene amplification, protein overexpression and/or a ligand-dependent autocrine/paracrine loop. Abnormalities in c-MET signaling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Significant progress has been made in advancement of c-MET pathway inhibitors through to clinical trials. A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being explored in phase I, II and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity with these agents, along with an acceptable toxicity profile. In this manuscript, the pharmacological profile of drugs targeting the c-MET pathway and available data from ongoing clinical trials of these drugs are discussed.

Original languageEnglish (US)
Pages (from-to)S37-S50
JournalTherapeutic Advances in Medical Oncology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Clinical Trials
Pharmaceutical Preparations
Neoplasms
Proto-Oncogene Proteins c-met
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Gene Amplification
Drug Delivery Systems
Drug Resistance
Pharmacology
Ligands
Mutation
Growth
Genes
Proteins

Keywords

  • c-MET
  • cabozantinib
  • foretinib
  • MetMAb
  • tivantinib

ASJC Scopus subject areas

  • Oncology

Cite this

In the clinic : Ongoing clinical trials evaluating c-MET-inhibiting drugs. / Sharma, Neelesh; Adjei, Alex.

In: Therapeutic Advances in Medical Oncology, Vol. 3, No. 1, 01.01.2011, p. S37-S50.

Research output: Contribution to journalReview article

@article{288692bd22ef4f04af1bc54f333cd8d7,
title = "In the clinic: Ongoing clinical trials evaluating c-MET-inhibiting drugs",
abstract = "The c-MET (mesenchymal–epithelial transition factor) pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination. The c-MET receptor tyrosine kinase can be activated via gene mutation, gene amplification, protein overexpression and/or a ligand-dependent autocrine/paracrine loop. Abnormalities in c-MET signaling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Significant progress has been made in advancement of c-MET pathway inhibitors through to clinical trials. A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being explored in phase I, II and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity with these agents, along with an acceptable toxicity profile. In this manuscript, the pharmacological profile of drugs targeting the c-MET pathway and available data from ongoing clinical trials of these drugs are discussed.",
keywords = "c-MET, cabozantinib, foretinib, MetMAb, tivantinib",
author = "Neelesh Sharma and Alex Adjei",
year = "2011",
month = "1",
day = "1",
doi = "10.1177/1758834011423403",
language = "English (US)",
volume = "3",
pages = "S37--S50",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - In the clinic

T2 - Ongoing clinical trials evaluating c-MET-inhibiting drugs

AU - Sharma, Neelesh

AU - Adjei, Alex

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The c-MET (mesenchymal–epithelial transition factor) pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination. The c-MET receptor tyrosine kinase can be activated via gene mutation, gene amplification, protein overexpression and/or a ligand-dependent autocrine/paracrine loop. Abnormalities in c-MET signaling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Significant progress has been made in advancement of c-MET pathway inhibitors through to clinical trials. A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being explored in phase I, II and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity with these agents, along with an acceptable toxicity profile. In this manuscript, the pharmacological profile of drugs targeting the c-MET pathway and available data from ongoing clinical trials of these drugs are discussed.

AB - The c-MET (mesenchymal–epithelial transition factor) pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination. The c-MET receptor tyrosine kinase can be activated via gene mutation, gene amplification, protein overexpression and/or a ligand-dependent autocrine/paracrine loop. Abnormalities in c-MET signaling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Significant progress has been made in advancement of c-MET pathway inhibitors through to clinical trials. A robust pipeline of high-quality inhibitors targeting different aspects of c-MET activation is currently being explored in phase I, II and III clinical trials across multiple tumor types. Preliminary data demonstrate promising clinical activity with these agents, along with an acceptable toxicity profile. In this manuscript, the pharmacological profile of drugs targeting the c-MET pathway and available data from ongoing clinical trials of these drugs are discussed.

KW - c-MET

KW - cabozantinib

KW - foretinib

KW - MetMAb

KW - tivantinib

UR - http://www.scopus.com/inward/record.url?scp=84998153455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998153455&partnerID=8YFLogxK

U2 - 10.1177/1758834011423403

DO - 10.1177/1758834011423403

M3 - Review article

AN - SCOPUS:84998153455

VL - 3

SP - S37-S50

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 1

ER -